GvHD is an important complication of allogeneic hematopoietic SCT. Parent-in-F1 models are frequently used to study GvHD immunobiology; the characteristics of parent-in-F1 GvHD vary between strain combinations and induction protocols. Here, we observed that a high-dose challenge of non-irradiated B6DBA2F1 and B6SJLF1 recipients with C57BL/6 splenocytes left the majority of recipients clinically healthy, while inducing progressive high-grade donor T-cell chimerism. We investigated this previously undescribed pattern of parent-in-F1 T-cell alloreactivity and studied the effect of serial parental splenocyte infusions on epithelial and lymphohematopoietic tissues. The majority of recipients of 4 weekly splenocyte infusions showed long-term survival with gradual establishment of high-grade donor chimerism and without any signs of epithelial-tissue GvHD. A minority of recipients showed BM failure type of GvHD and, respectively, graft rejection. Moreover, long-term F1 chimeras showed protracted pancytopenia, and in peripheral lymphoid tissues severe lymphopenia and near-complete eradication of APCs and dysfunction in antigen-presenting capacity in remaining APC. Hematopoiesis and lymphoid tissue composition recovered only after multilineage donor chimerism had established. In conclusion, we report on a novel type of parent-in-F1 hybrid GvHD, where a cumulative high dose of C57BL/6 parental splenocytes in non-irradiated F1 mice induces subclinical but severe hematolymphoid-tissue GvHD, causing prolonged immuno-incompetence.
Introduction
GvHD remains an important complication after allogeneic hematopoietic SCT, in particular in the context of donor lymphocyte infusion (DLI) therapy for induction of GvL effects. 1 In recent years, substantial progress has been made in the understanding of the immunobiology of DLIassociated GvHD and GvL effects. Mouse studies have shown that recipient APCs residing in epithelial tissues are critical targets for alloreactive T cells in the induction of GvHD, 2 and that local inflammation, such as that resulting from pretransplant conditioning, is a prerequisite for the migration of alloreactive T cells into these GvHD target tissues. 3 Indeed, abatement of conditioning-induced inflammation is thought to contribute to the observed reduced GvHD risk when DLI is delayed with several weeks or months after a transplant. [4] [5] [6] [7] [8] [9] In contrast, the GvL response of DLI has been shown in mice to result from the interaction between donor T cells and recipient APC in the lymphohematopoietic tissues, resulting in a lymphohematopoietic GvH reaction (LHGvHR). 2 In mice, mixed chimerism and a LHGvHR with conversion of mixed to full donor chimerism have been shown essential for GvL responses after DLI. 8, 9 Moreover in the clinical setting, antitumor responses after DLI frequently occur in association with conversion of mixed to full donor T-cell chimerism. 10, 11 Parent-in-F1 models are frequently used to study the immunobiology of GvHD. 12, 13 Earlier studies in the C57BL/6-B6DBA2F1 model showed that high-dose C57BL/6 splenocytes induce acute epithelial-tissue GvHD that is lethal over several months. 14 In contrast, high-dose C57BL/6 lymph node (LN) cells induces a BM failure type of GvHD (BMGvHD), which is rapidly lethal; [15] [16] [17] BMGvHD is also seen if recipients are irradiated, in which case lower quantities of C57BL/6 T cells are required. The characteristics of parent-in-F1 GvHD is equally known to vary between strain combinations, and to depend on strainspecific alloreactive T-cell-precursor frequency. 18 We here made the interesting observation in the C57BL6-B6DBA2F1 model that a high-dose challenge with parental splenocytes in non-irradiated recipients caused typical BMGvHD in only 1/3 of recipient mice. The majority of recipient mice remained clinically healthy, while they showed progressive evolution towards complete donor T-cell chimerism. A similar evolution was seen in C57BL/ 6-B6SJLF1 mice. This pattern of parent-in-F1 alloreactivity has so far not been reported on, and we document here that this represents a form of subclinical GvHD with severe lymphoid-tissue GvH reactivity causing prolonged immuno-incompetence. These data may hold implications for DLI strategies in non-myeloablative transplant regimens, which aim at inducing strong lymphohematopoietic GvH reactivity in the absence of conditioning-related inflammation. female mice as donors, and purchased from Janvier (Le Genest Saint Isle, France). Recipients were housed in individually ventilated cages; during procedures, animals were kept under laminar flow. Diet consisted of standardized pellet chow and UV-decontaminated water. All experiments were approved by the local ethical committee.
Materials and methods

Animals
BM transplantation and parental splenocyte infusion
In the serial parental splenocyte infusion (PSI) model, B6DBA2F1 or B6SJLF1 animals were used as recipients and given 4 weekly IV injections of 25 Â 10 6 , respectively, 50 Â 10 6 C57BL/6 splenocytes. In the allogeneic BM transplant (BMT) model, B6SJLF1 mice were given 9.5 Gy TBI (linear accelerator 18 MEV photons (General Electric, Baden, Germany), dose rate 3.9 Gy/min with focus-tomidbody distance 100 cm) and IV infusion of 5 Â 10 6 T-cell-depleted (described earlier 19 ) C57BL/6 BM cells.
Leukemia challenge
For GvL studies, the P815 cell line (DBA2 mouse mastocytoma, ATCC, H2K d ) was used. Cells from frozen stock were maintained in vitro for a limited number of passages. For each experiment, the in vivo behavior was verified by inoculating naive host-type mice. BM chimeras were challenged IV with 5 Â 10 5 leukemia cells 7 days after the first PSI.
Animal follow-up Clinical monitoring. Animals were inspected daily for weight loss, signs of acute GvHD affecting general condition and epithelial organs, 20 leukemic disease and mortality.
Donor chimerism. Peripheral blood lineage-specific donor chimerism was studied using flowcytometry (FACStarPlus, FACSCanto, BD Biosciences, Erembodegem, Belgium), as described earlier, 21 using mAb against CD3; CD45R/B220; CD11c; CD11b; H-2K Histopathology. Moribund animals were killed for histopathology: following standard fixation procedures, paraffin-embedded sections were prepared and stained with hematoxylin-eosin H&E. Pictures were taken with a Zeiss Axioplan-2 microscope (Carl Zeiss AG, Go¨ttingen, Germany) equipped with a cooled charge-coupled device camera COHU 4910 (Diagnostic Instruments, Detroit, MI, USA) or a Leica DM LB2 microscope (Leica Microsystem, Groot Bijgaarden, Belgium) equipped with a Nicon HC L3TP camera (Nikon Belux, Brussels, Belgium).
Cell phenotypic studies. Cellular compositions of BM, spleen and LNs were studied by flowcytometry (as described earlier). Total cell counts were enumerated manually using Trypan Blue Exclusion. Complete blood counts (CBCs) were determined using a Cell Dyn 3500R (Abbott Diagnostics, Ottignies/Louvain-La-Neuve, Belgium). The normal range of CBC values was determined in a group of 5-7 age-matched naive F1 mice. Values in experimental mice were considered abnormal if lower or higher than the mean±2 s.d. from this control group.
Induction of experimental autoimmune encephalomyelitis and in vitro stimulation assays Induction of experimental autoimmune encephalomyelitis. Experimental autoimmune encephalomyelitis (EAE) was induced by bilateral hind-footpad injection of myelin oligodendrocyte glycoprotein (MOG ) peptide (Sigma-Aldrich, Bornem, Belgium), heat-killed Mycobacterium Tuberculosis in CFA (BD Biosciences) and IV injection of Bordetella Pertussis toxin (Sigma-Aldrich), as described earlier. 22 In vitro stimulation assays. EAE-induced chimeras were killed on day 10. Popliteal LN cells (LNc) were stimulated with MOG 35-55, as described earlier. 22 In brief, LNc were plated (2 Â 10 5 cells/well, quadruplicate) in stimulation medium (RPMI containing Na pyruvate; NEAA; L-glutamine; 2-ME; FCS) together with 2 Â 10 5 Mitomycin-C-treated (Kyowa Hakko Kogyo, Tokyo, Japan) host-type splenocytes (as APC source). MOG was added at 10 mg/mL, or ConA at 6 mg/mL ConA. After 4-day culture, [ 3 H]thymidine-incorporation was determined (c.p.m.), as described earlier. 22 Results are expressed as stimulation index ¼ c.p.m. of stimulated/c.p.m. of non-stimulated cells.
MOG -specific T-cell proliferation assay. B6SJLF1 mice were immunized as described and killed on day 10. Popliteal LNc were stimulated for 72 h at 4 Â 10 6 cells/mL in stimulation medium containing 20 mg/mL MOG . T cells were subsequently expanded in RPMI containing 10% FCS and 20 U/mL rIL-2 for 5-7 days. Finally, 4 Â 10 4 T cells were re-stimulated with 10 mg/mL MOG in the presence of 0.8 Â 10
6 Mitomycin-C-treated splenocytes or LNc (from chimeric or naive mice). [ 3 H]Thymidine incorporation was determined as described above.
MLR MLR was performed as described earlier. 21 In brief, responder cells were nylon wool-enriched splenocytes of naive C57BL/6 mice, and stimulator cells Mitomycin-C-treated LNc or splenocytes from chimeras or naive host-type mice. After 5-day culture, [ 
Statistical analysis
The Mann-Whitney U test was used to estimate the level of statistical significance of difference between groups of data, and the log-rank test to test the difference in survival between groups (Po0.05 was considered as evidence for statistical significance).
Results
Repetitive parental C57BL/6 splenocyte infusion in unconditioned B6DBA2F1 recipients can induce progressive engraftment without clinical GvHD B6DBA2F1 recipients were given 4 weekly PSIs of 25 Â 10 6 C57BL/6 splenocytes. Two patterns of clinical outcome and chimerism evolution were documented. Approximately 1/3 of recipients exhibited rapidly progressive donor T-cell chimerism (arbitrarily defined as 440% on day 14), reaching 490% around day 30 ( Figure 1a ). This evolution was associated with a mortality rate of 79% by day 42 (Figure 1b) , the animals experienced sudden death without significant weight loss (Figure 1c) or clinical pathological signs. In a separate experiment, moribund animals in this early phase were killed: peripheral blood CBC showed pancytopenia (Table 1) ; BM histology ( Figure 2a) showed dilated sinuses, depletion of hematopoiesis with absent erythropoiesis, maturation arrest of the myeloid lineage and dysplastic megakaryocytes, residual dendritic reticulum cell background and presence of lymphocytes. This is consistent with the previously described C57BL/6-B6DBA2F1 form of BM failure type of acute GvHD. 15 The majority of recipients, however, showed a gradual increase of donor T-cell chimerism (defined as o40% on day 14), reaching 490% around day 90 (Figure 1a) . This was associated with 84% long-term survival ( Figure 1b ) and a favorable weight evolution (Figure 1c) , and none of the animals showed clinical signs of acute epithelial GvHD (not shown). CBC analysis in long-term surviving animals equally showed pancytopenia, with recovery of cell counts in all lineages after day 61 ( Figure 3 ), suggesting that low-grade mortality was equally due to BM failure; indeed, Figure 1 Evolution of donor T-cell chimerism, weight, survival and survival after leukemia challenge in the C57BL/6-B6DBA2F1 chimeras. B6DBA2F1 recipients given parental splenocyte infusions (PSI) were stratified according to the pattern of donor T-cell chimerism evolution. (a) Evolution of donor T-cell chimerism: animals showing X40% T-cell donor chimerism on day 14 after the first infusion were assigned to the 'F1 rapid'-group (n ¼ 37) and those showing o40% T-cell donor chimerism were assigned to the 'F1 gradual'-group (n ¼ 84). (b) Kaplan-Meier survival curves showing the survival of the 'F1 rapid'-and the 'F1 gradual'-group, as well as that of a group of naive host-type mice that were included in each experiment as controls (control F1). Results in panels a and b are from 16 similarly designed experiments. *Po0.05 between 'F1 rapid' and 'F1 gradual' (log-rank). (c) Weight evolution (expressed as mean±s.d. percentage of individual starting weights) in the 'F1 rapid'-group (n ¼ 12, long-term survivors n ¼ 4), the 'F1 gradual'-group (n ¼ 74), and a group of host-type control animals (n ¼ 76). Results are from 12 similarly designed experiments. (d) B6DBA2F1 mice given repetitive C57BL/6 infusion (F1 chimera), and age-matched naive B6DBA2F1 mice not given PSI (control F1) were challenged with 5 Â 10 5 P815 leukemia cells on day 7. Kaplan-Meier survival curve is shown of a total of 27 F1 chimera and 13 control F1 animals, from four identically designed experiments, which included simultaneous testing of all three groups. *Po0.05 for the difference in survival between groups (log-rank).
BM histology of moribund mice was similar to that of moribund animals in the early mortality group (as in Figure 2a ).
These data indicate that strong LHGvH reactivity occurs with repetitive PSI. As this type of alloreactivity is exploited by DLI strategies to obtain GvL effects, in a next set of experiments we investigated whether repetitive PSI would allow for a GvL response. One week after the first PSI, chimeric B6DBA2F1 recipients were challenged with 5 Â 10 5 P815 cells. PSI-treated animals showed a significant survival benefit over naive host-type animals, with long-term survival of 37% (Figure 1d ). Histopathology in moribund animals confirmed tumor infiltration in LN, liver, spleen, salivary gland, muscle and BM (not shown). Thus, in unconditioned F1 recipients, repetitive PSI can establish strong LHGvHR with a gradual evolution to high-grade donor chimerism, and with a strong GvL response. Despite the high cumulative T-cell dose, this occurs without acute epithelial GvHD. However, although rapid institution of donor T-cell chimerism is associated with rapidly lethal BMGvHD, the gradual course is equally accompanied by prolonged pancytopenia, indicating the development of subclinical BMGvHD that is severe but that holds a significantly lower mortality risk.
To determine whether the additional infusion of donor stem cells would alter the characteristics of the GvHR, we determined the effect of serial PSI in F1 recipients where donor BM was coinfused with the parental splenocyte inoculums. F1 recipients were challenged with serial PSIs only, or with serial PSIs and 5 Â 10 6 T-cell-depleted C57BL/6 BM cells at the first or the third PSI. CBC were sequentially determined but showed that coinfusion of BM cells influenced neither the severity nor the duration of pancytopenia (Figures 3b and c) .
The serial PSI regimen induces a disruption of the cellular composition of lymphohematopoietic organs The pattern of parent-in-F1 alloreactivity that allows progressive donor chimerism and GvL with good overall tolerance and long-term survival has previously not been reported. The effects on peripheral blood CBC are indicative of subclinical GvHD targeting BM function. We further explored the extent of this subclinical GvHD by evaluating the cellular composition and histological appearance of lymphoid and hematopoietic tissues, and epithelial GvHD target tissues. Groups of three B6DBA2F1 mice receiving serial splenocyte infusions were killed at selected time points, as indicated in Figure 4 . None of the animals showed histological signs of acute epithelial GvHD, or chronic SLE-like GvHD (for example immunecomplex glomerulonephritis) previously reported in F1 hybrids 23 (not shown). Total cell counts and proportions of T, B and myeloid cells were determined on spleen, BM and LN (Figures 4a-c) . Results were expressed relative to the mean value obtained in a group of three naive B6DBA2F1 mice that were analyzed at each time point. The chimeras showed a transient expansion of total cell numbers, followed by a progressive decline in spleen and LN cell counts beyond day 84, and a temporary decrease in BM cell counts with normalization by day 84 (Figure 4a) . Analysis of the cell subpopulations in spleens and LN (Figures 4b  and c) showed a 2-week phase of lymphoproliferation and a myeloid cell expansion, followed by a progressive decline in these cell lineages.
Lymphoproliferation probably is a result of alloreactive T-cell proliferation in BM and lymphoid organs. The expanding CD11b þ population showed a CD11b þ F4/ 80
hi phenotype, and a morphology typical of myeloid progenitor cells (not shown), similar to those previously described in BM chimeras after myeloablation. 9, 21 We postulate therefore that this peripheral expansion of myeloid progenitor cells occurs as a consequence of the BM depression caused by alloreactive T cells. In conclusion, in addition to causing subclinical BMGvHD, the serial PSI regimen induces a profound disruption of the cellular composition of lymphohematopoietic organs. The cellular disruption of the lymphoid organs after serial PSIs includes an APC defect Immune function requires a functional APC compartment, and host-type APC have a critical role in the development of GvL and GvHD. 2, 8, 24, 25 We specifically investigated the evolution of host-type APC in the C57BL/6-B6DBA2F1 model, but also in the similar C57BL/6-B6SJLF1 combination. In the latter model, we also recently showed that 60% of non-irradiated B6SJLF1 recipients develop high-grade donor chimerism while remaining clinically healthy, whereas 40% of them rejected the parental splenocyte grafts. 22 We also showed that such C57BL/6-B6SJLF1 chimeras become resistant to the development of MOG 35-55 -induced EAE. 22 Induction of EAE by footpad injection of MOG peptide/CFA relies on the presentation of MOG peptide by APC in the draining popliteal LN. We hypothesized that-in view of the lymphohematopoietic changes seen in C57BL/6-B6DBA2F1 chimeras, which included a profound decline in CD11c þ cells (Figure 4c )-the resistance to EAE induction in long-term C57BL/6-B6SJLF1 chimeras relates to disappearance of APC in draining LN. Both C57BL/6-B6SJLF1 and C57BL/6-B6DBA2F1 models were used to study the evolution of APC in more detail.
First, we confirmed that long-term surviving C57BL/6-B6SJLF1 chimeras exhibit a similar disruption of the lymphohematopoietic system (Figure 4d ): spleen and LN equally showed a consecutive expansion and depletion of myeloid and lymphoid elements, and, in particular, a marked reduction in total CD11c þ cell counts (Figures 4e  and f) . Of note, a difference in the kinetics was seen in the two models, with the myeloid expansion showing a more protracted course in the B6SJLF1 mice (Figure 4) . Histology of lymphoid organs on day 60 showed disruption of the normal architecture of LN (Figure 2c ) and spleen (not shown): LN were largely depleted of lymphocytes, and, in accordance with flowcytometry data, in B6SJLF1 mice they showed a prominent presence of myeloid progenitor cells.
Next, LNc of these PSI chimeras were used in in vitro assays to document the functional presence or absence of APC. LNc derived from C57BL/6-B6SJLF1 chimeras (on day 56 after the first splenocyte infusion) and from naive B6SJLF1 mice were used as APC source in a MOG -specific B6SJLF1 T-cell proliferation assay or as stimulators in allogeneic MLR. In contrast to naive B6SJLF1 LNc, LNc from C57BL/6-B6SJLF1 chimeras supported neither the MOG-specific proliferative T-cell response (Figure 5a ), nor the MLR response of C57BL/6 responder cells (Figure 5b ). In the latter setting, coculture with T-cell-depleted B6SJLF1 splenocytes (as an additional source of host-type APC) restored the MLR reaction (Figure 5b) . From the flowcytometric and these functional data, we conclude that the disruption of lymphoid organs in B6SJLF1 chimeras includes a quantitative defect in host-type APC. However, LN of C57BL/6-B6SJLF1 chimeras contain a considerable proportion of myeloid progenitor cells (Figures 2c and 4f) , which may act as suppressor cells and account for the lack of proliferative T-cell responses in vitro. 21 Therefore, similar MLR experiments were performed using cells from B6DBA2F1 chimeras, where myeloid progenitor cells disappear more rapidly (Figures 2d and  4c) . Spleen cells and LN cells from chimeras challenged with PSIs only, or challenged with PSIs together with BM cells were used as stimulator cells for C57BL/6 T cells in MLR. In this particular experiment, day 73 chimeras showed persistent cytopenia in LN and spleens (not shown), but importantly, the frequencies of CD11b þ and CD11c þ cells had normalized relative to naive F1 mice, whereas host chimerism in CD11c þ cells was still 480% (not shown). We found that spleen and LN cells from these chimeras were poor stimulators for naive C57BL/6 responder cells (Figures 5c and d) . Although purified APC were not tested owing to insufficient cell yield from the severely cytopenic lymphoid organs, the data suggest that-in addition to a quantitative defect in APC numbers-long-term PSI chimeras may also develop a qualitative dysfunction of residual APC.
Long-term surviving PSIs chimeras do not exhibit general T-cell hyporesponsiveness
In view of the profound lymphopenia in long-term F1 chimeras induced by PSIs, we examined T-cell function. We previously showed that, in contrast to EAE-induced B6SJLF1 control mice, splenocytes from C57BL/6-B6SJLF1 chimeras fail to exhibit an in vitro MOG 35-55 -specific proliferative response. 22 Here, we confirmed that LNc from such chimeras (taken on day 56 after the start of PSIs, 14 days after MOG challenge) also fail to generate a MOG-specific proliferative response, but exhibit a vigorous response to ConA (Figure 5e ). Next, we tested splenocytes from C57BL/6-B6SJLF1 chimeras (taken on day 56) in MLR with splenocytes from naive B6SJLF1 or BALB/c. Splenocytes from naive B6SJLF1 and C57BL/6-B6SJLF1 radiation chimeras (alloBMT/F1, see Materials and methods) were tested as positive and negative controls, respectively. The MLR response against third party was comparable in all groups, whereas only C57BL/6-B6SJLF1 splenocyte infusion chimeras showed a significant anti-B6SJLF1 response (Figure 5f ). These data indicate that T cells from PSI chimeras readily respond to ConA, allogeneic and third-party targets, and that-despite severe lymphopenia-the disruptive effect on the lymphoid organs does not include a state of general T-cell hyporesponsiveness.
Lymphohematopoietic recovery in long-term PSI chimeras parallels establishment of multilineage donor chimerism Finally, we illustrated that CBC in B6DBA2F1 PSI chimeras evolved in parallel with the level of donor T-cell chimerism (Figure 3c ), as most animals showed recovery of cell counts on day 77 together with nearcomplete donor T-cell chimerism. This suggested that recovered lymphohematopoiesis was derived from donor-type stem cells. In LN of long-term (day 88) B6DBA2F1 PSI chimeras, we documented that high-grade donor chimerism had established in not only the T-cell lineage (94% ± 0.7 s.e.) but also in B cells (90% ± 1.3 s.e.) and dendritic cells (65% ± 3.2 s.e.). Similar results were obtained in spleen cells, with-in addition-high-grade donor chimerism in the CD11b þ lineage (80% ±1.6 s.e.) (data from one out of two representative experiments).
Discussion
We here report on a previously undescribed pattern of GvH reactivity in the well-known C57BL/6-B6DBA2F1 parent-in-F1 hybrid mouse model. We found that serial infusions of parental splenocytes, establishing a cumulative high dose of alloreactive lymphocytes, can lead to a strong LHGvH response resulting in a form of subclinical GvHD with profound perturbation of lymphohematopoietic tissues, including a depletion of peripheral APCs with associated prolonged immune incompetence. The C57BL/6-B6DBA2F1 model is considered a wellestablished model GvHD, 12, 13 but GvHD characteristics vary according to the induction protocol. Reportedly, highdose C57BL/6 splenocytes induce acute epithelial GvHD that is lethal over several months.
14 In contrast, high-dose C57BL/6 LN cells induces a BMGvHD, which is rapidly lethal; [15] [16] [17] BMGvHD is also seen if recipients are irradiated, in which case lower quantities of C57BL/6 T cells are required. Here, we found that challenge of B6DBA2F1 with C57BL/6 splenocytes gave rise to two distinct outcome patterns. Only 1/3 of recipients developed lethal BMGvHD; the majority exhibited progressive institution of high-grade donor T-cell chimerism with good clinical tolerance, long-term survival and no histological evidence of acute epithelial-tissue GvHD. However, subclinically these animals showed protracted pancytopenia, and in lymphoid tissues prolonged lymphopenia and a near-complete eradication of APCs. This pattern of lymphohematopoietic GvHD has previously not been reported.
Our recipient mice were housed in semi-SPF conditions; hence, variability in intestinal colonization and inflammation may be one of the factors determining to which extent parental splenocyte inocula produce alloactivated cytotoxic T cells 26, 27 and produce either rapidly lethal or subclinical GvHD. In this respect, Murai et al. 28 showed that C57BL/6 splenocyte inoculation in unirradiated B6DBA2F1 resulted in a rapid and preferential accumulation of donor CD8 þ T cells in Peyer's patches before initiation of GvHD. We assume that a reduced inflammatory-prone intestinal environment protected some mice from aggressive BMGvHD; however, the resistance of these animals to cumulative high-dose PSI, while developing high-grade donor chimerism was striking. The data indicate that this relates to a delicate balance between donor T cells and host APC in a non-inflammatory environment.
The pattern of lymphohematopoietic subclinical GvHD could be reproducibly obtained in both B6DBA2F1 and B6SJLF1 hybrids challenged with C57BL/6 parental cells, with a slight difference only in the kinetics of the cellular changes. Both models showed a severe quantitative reduction in dendritic cells in spleens and LN, and ex vivo MLR and MOG-specific T-cell assays showed that the stimulatory capacity of whole spleen and LN cells of B6SJLF1 mice was defective. Further, the observation that parental T cells failed to proliferate when stimulated with B6D2F1 chimeric LN or spleen cells in which relative numbers of CD11c þ cells (that were still largely host derived) had normalized relative to naive F1 mice, suggests that lymphohematopoietic alloreactivity may also affect the function of residual APC. Together, the data indicate that a quantitative defect, and possibly also a qualitative defect of APC may underlie the resistance of these chimeras to the GvHD-inducing capacity of repeated splenocyte inocula and their resistance to EAE induction. 22 In the B6SJLF1 model, where myeloid cell expansion is more protracted, an extrinsic regulatory role of these cells on the observed in vitro T-cell proliferative responses cannot be excluded. The expansion of myeloid progenitor cells in these chimeras is reminiscent of the myeloid-derived suppressor cells described in association with myelosuppression, GvHD, tumors and chronic infections 21, 29 where they have been implicated in tumor-specific and nonspecific T-cell dysfunction. [30] [31] [32] Our earlier data, 21 and more recently those of others, 33 suggest that these cells may have a role in controlling GvH reactivity. Whether they contribute in this model to confining GvH reactivity to the lymphohematopoietic system is the subject of ongoing investigations.
Interestingly, Wang et al. 34 recently showed in a similar C57BL/6-B6DBA2F1 model involving recipient irradiation that IFN-g promotes the allospecific LHGvH response, but attenuates the potential of alloreactive T cells to mediate epithelial-tissue GvHD. Irradiation is known to influence the activation/migration of allospecific T cells, 3 and the outcome of parent-in-F1 GvHD. 35 Assuming that also in our irradiation-free model, IFN-g has a critical role in LHGvH, blockade of this pathway would potentially reduce the risk for severe immunoincompetence. However, such a limitation of LHGvH responses could equally limit GvL effects, which, as in the current model, occur in association with LHGvH reactivity.
Coinfusion of donor BM with parental splenocytes, either at the first challenge in naive mice or at the third challenge when cytopenia (and therefore space in the recipient marrow) was already established, influenced neither the severity nor the duration of pancytopenia in our model, and flow cytometric studies and in vitro assays showed that the defect in APC numbers and APC function was equally profound in these animals. We further showed that in irradiated B6C3HF1 mice, the coinfusion of C57BL/ 6 spleen cells (as a source of hematopoietic stem cells) with purified C57BL/6 T cells can rescue mice from early death and converts BMGvHD into acute epithelial-tissue GvHD (not shown); this effect was not seen when F1 BM was coinfused, indicating that there was no innocent bystander destruction of donor-type hematopoietic stem cells. This had been earlier demonstrated by Rozendaal et al. 36 in the DBA/2-B6D2F1 model. In contrast, Chen et al. 16, 17 have shown in the C57BL/6-CByB6F1 model that the BM of F1 mice with BMGvHD not only fails to form stromal feeder layers in vitro, but also contains T cells capable of destroying fresh donor-type stem cells as well, indicating that in this model innocent bystander destruction of both stromal and hematopoietic progenitor cells is taking place. In contrast to these studies, the model we present here does not include irradiation, and inflammation may influence the degree to which bystander destruction is taking place. The data, however, argue against bystander destruction of donor-type stem cells, as the eventual lymphomyeloid reconstitution is predominantly donor derived; in contrast, the data suggest that repeated challenges with PSIs target the BM stroma, which fails to support effective myelohematopoiesis until T-cell alloreactivity has subsided. These data reveal a delicate balance between donor T cell, donor stem cell and BM stromal function.
Although this experimental model of unidirectional T-cell alloreactivity presents some limitations with regard to extrapolations to the clinical situation, the data may be relevant to the development of clinical DLI strategies. They indicate that a challenge with non-tolerant T cells in an inflammation-free tolerant recipient can lead to severe subclinical lymphoid-tissue GvHD causing prolonged immuno-incompetence. The haploidentical pattern of T-cell alloreactivity is not entirely representative of the clinical situation where most patients receive an MHCmatched graft. Haploidentical DLI in humans is expected to carry a high risk of causing epithelial GvHD, although our data in this study indicate that this may depend on a delicate balance. Of note, there is a growing interest in haploidentical stem cell transplantation, 11 and both delayed graft function and delayed immune recovery have been reported as complications after MHC-mismatched BM transplantation, 37 supporting the potential relevance of our data.
